Chromogranin A in the diagnosis of pheochromocytoma: review

Cover Page

Cite item

Full Text

Abstract

Pheochromocytoma is a tumor of neuroectodermal origin, which arises from chromaffin cells of the sympatho-adrenal system of the adrenal or extra-аdrenal localization, secreting an excessive amount of catecholamines, and accompanies with the syndrome of hypertension of varying degrees of severity and diverse metabolic disorders. In addition to the synthesis and secretion of catecholamines, these tumors are able to produce a variety of biologically active peptides, including chromogranin A (neuroendocrine secretory protein), which, along with other laboratory tests, can help in the diagnosis of pheochromocytoma.

About the authors

M. Yu Yukina

National Medical Research Center of Endocrinology of the Ministry of Health of Russian Federation

Email: endo-yukina@yandex.ru
канд. мед. наук, вед. науч. сотр. отд. терапевтической эндокринологии 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11

D. A Davtyan

National Medical Research Center of Endocrinology of the Ministry of Health of Russian Federation

Email: diadavtyan@gmail.com
117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11

E. A Troshina

National Medical Research Center of Endocrinology of the Ministry of Health of Russian Federation

Email: troshina@inbox.ru
чл.-кор. РАН, д-р мед. наук, проф., зав. отд. терапевтической эндокринологии 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11

N. M Platonova

National Medical Research Center of Endocrinology of the Ministry of Health of Russian Federation

Email: doc-platonova@inbox.ru
д-р мед. наук, гл. науч. сотр. отд. терапевтической эндокринологии 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11

References

  1. Tischler A.S. Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas. Endocr Pathol 2006; 17: 321-8.
  2. Lenders J.WM, Quan-Yang Duh, Eisenhofer G et al. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (6): 1915-42.
  3. Eisenhofer G, Pacak K, Huynh T.T et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 2011; 18 (1): 97-111.
  4. Därr R, Lenders J.W.M, Hofbauer L.C et al. Pheochromocytoma: Update on Disease Management. Ther Adv in Endo and Metab 2012; 3 (1): 11-26.
  5. Gunawardane K.P.T, Grossman A. The clinical genetics of phaeochromocytomа and paraganglioma. Arch Endocrinol Metab 2017; 61 (5): 490-500.
  6. Martucci V.L, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer 2014; 38 (1): 7-41.
  7. Chen H, Sippel R.S, O'Dorisio M.S et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39: 775-83.
  8. McNeil A.R, Blok B.H, Koelmeyer T.D et al. Phaeochromocytomas discovered during coronial, autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000; 30: 648-52.
  9. Mannelli M, Lenders J.W.M, Pacak K et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012; 26: 507-15.
  10. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary, hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193-202.
  11. Tucker M.E. Endocrine Society first to address rare adrenal-tumor care. Medscape Medical News 2014; June 5.
  12. Chen Y, Xiao H, Zhou X et al. Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Endocr Pract 2017; Jul 13.
  13. Lenders J.W, Pacak K, Walther M.M et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287 (11): 1427-34.
  14. de Jong W.H, Eisenhofer G, Post W.J et al. Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors. J Clin Endocrinol Metab 2009; 94 (8): 2841-9.
  15. Algeciras-Schimnich A, Preissner C.M, Young W.F et al. Plasma chromogranin a or urine fractionated metanephrines, follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93 (1): 91-5.
  16. Tasiemski A, Hammad H, Vandenbulcke F et al. Presence of chromogranin-derived antimicrobial peptides in plasma during, coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 2002; 100: 553-9.
  17. Helle K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769-94.
  18. Banks P, Helle K. The release of protein from the stimulated adrenal medulla. Biochem J 1965; 97: 40C-1C.
  19. Lee R.W, Huttner W.B. Tyrosine-O-sulfated proteins of PC12 pheochromocytoma cells and their sulfation by a tyrosylprotein sulfotransferase. J Biol Chem 1983; 258: 11326-34.
  20. Rosa P, Hille A, Lee R.W et al. Secretogranins I and II: two tyrosine-sulfated secretory proteins common to a variety of cells secreting peptides by the regulated pathway. J Cell Biol 1985; 101: 1999-2011.
  21. Guérin M, Guillemot J, Thouënnon E et al. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regul Pept 2010; 165 (1): 21-9.
  22. https://www.alpco.com/chromoa-chromogranin-a-elisa
  23. d'Herbomez M, Do Cao C, Vezzosi D et al. Sep, groupe des tumeurs endocrines (GTE France). Chromogranin A assay in clinical practice. Ann Endocrinol (Paris) 2010; 71 (4): 274-80.
  24. Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 967-73.
  25. Adolf K, Wagner L, Bergh A et al. Secretagogin is a new neuroendocrine marker in the human prostate. Prostate 2007; 67: 472-84.
  26. Hsiao R.J, Parmer R.J, Takiyyuddin M.A, O'Connor D.T. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore). 1991; 70 (1): 33-45.
  27. d'Herbomez M, Forzy G, Bauters C et al. An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol 2007; 156 (5): 569-75.
  28. Giovanella L, Ceriani L, Balerna M et al. Diagnostic value of serum chromogranin-A combined with MIBG scintigraphy inpatients with adrenal incidentalomas. Q J Nucl Med Mol Imaging 2008; 52 (1): 84-8.
  29. Glinicki P, Jeske W, Bednarek-Papierska L et al. Chromogranin A (CgA) in adrenal tumours. Endokrynol Pol 2013; 64 (5): 358-62.
  30. Guillemot J, Guérin M, Thouënnon E et al. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma. PLoS One 2014; 9 (2): e88698.
  31. Bílek R, Zelinka T, Vlček P et al. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. Physiol Res 2017; 66 (Suppl. 3): S397-S408.
  32. Pregun I, Herszényi L, Juhász M et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84 (1): 22-8.
  33. Hsiao R.J, Mezger M.S, O'Connor D.T. Chromogranin A in uremia: progressive retention of immunoreactive fragments. Kidney Int 1990; 37 (3): 955-64.
  34. Pieroni M, Corti A, Tota B et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 2007; 28 (9): 1117-27.
  35. Di Comite G, Rossi C.M., Marinosci A et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol 2009; 85 (1): 81-7.
  36. Valeur J, Milde A.M, Helle K.B, Berstad A. Low serum chromogranin A in patients with self-reported food hypersensitivity. Scand J Gastroenterol 2008; 43 (11): 1403-4.
  37. Fossmark R, Jianu C.S, Martinsen T.C et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol 2008; 43 (1): 20-4.
  38. Ardill J.E, O'Dorisio T.M. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators. Endocrinol Metab Clin North Am 2010; 39 (4): 777-90.
  39. Srivastava A, Padilla O, Fischer-Colbrie R. et al. Neuroendocrine secretory protein-55 (NESP-55) expression discriminates pancreatic endocrine tumors and pheochromocytomas from gastrointestinal and pulmonary carcinoids.Am J Surg Pathol 2004; 28 (10): 1371-8.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies